Targeting IRAK1/4 as an effective treatment for MDS/AML induced by mutant ASXL1

Naru Sato

Presentation information

Oral Session

Oral Session 2-11B AML: Novel therapeutic targets

Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.11 (Osaka International Convention Center, 10F 1004-5)

Chair: Yoichi Imai (Research Hospital, The Instisute of Medical Science, The University of Tokyo, Japan)

[OS2-11B-4] Targeting IRAK1/4 as an effective treatment for MDS/AML induced by mutant ASXL1

Naru Sato¹, Susumu Goyama¹, Xiaoxiao Liu¹, Takeshi Fujino¹, Taishi Yonezawa¹, Hitoshi Takizawa², Satoshi Yamasaki³, Tatsuhiro Shibata³, Toshio Kitamura¹ (1.Division of Cellular Therapy, IMS,Tokyo Univ., 2.IRCMS, Kumamoto Univ.,, 3.Laboratory of Molecular Medicine, Human Genome Center, IMS,Tokyo Univ.)

Abstract password authentication.
Password is written on a program and abstract book.